Alkermes (NASDAQ:ALKS) Releases Earnings Results, Beats Estimates By $0.11 EPS

Alkermes (NASDAQ:ALKS) posted its earnings results on Wednesday. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.81 by $0.11, Zacks reports. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Stock Up 3.0 %

NASDAQ ALKS traded up $0.95 during trading hours on Wednesday, hitting $32.91. 476,058 shares of the company traded hands, compared to its average volume of 1,500,044. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The business’s 50-day moving average is $30.11 and its 200-day moving average is $28.62. The stock has a market capitalization of $5.32 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.83 and a beta of 0.49. Alkermes has a twelve month low of $22.90 and a twelve month high of $32.88.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ALKS. Piper Sandler reissued an “overweight” rating and set a $37.00 price objective (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. JPMorgan Chase & Co. cut their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $37.00 price target on shares of Alkermes in a research report on Friday, October 25th. The Goldman Sachs Group dropped their price objective on shares of Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, October 25th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Alkermes in a report on Tuesday. They issued a “buy” rating and a $40.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.33.

Insiders Place Their Bets

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This trade represents a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Craig C. Hopkinson sold 100,918 shares of Alkermes stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the completion of the transaction, the executive vice president now directly owns 44,290 shares of the company’s stock, valued at approximately $1,419,494.50. This trade represents a 69.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 179,189 shares of company stock valued at $5,723,518 in the last 90 days. 4.89% of the stock is currently owned by insiders.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.